Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current molecular medicine

• Publication date

  2009-11-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/156652409789839125PMID 19747110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

  2009cited by this paper
• ABC multidrug transporters: structure, function and role in chemoresistance.

  2008cited by this paper
• Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas

  2008cited by this paper
• Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters

  2008cited by this paper
• Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma.

  2008cited by this paper
• Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract

  2007cited by this paper
• Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer

  2007cited by this paper
• The ABCA subfamily—gene and protein structures, functions and associated hereditary diseases

  2007cited by this paper
• Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2

  2007cited by this paper
• Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

  2007cited by this paper
• Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.

  2007cited by this paper
• TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

  2007cited by this paper
• Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.

  2007cited by this paper
• Expression of Nuclear Factor-kappaB Family Proteins in Hepatocellular Carcinomas

  2007cited by this paper
• MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation

  2007cited by this paper
• Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

  2007cited by this paper
• In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.

  2007cited by this paper
• ABCA1, from pathology to membrane function

  2007cited by this paper
• The apical conjugate efflux pump ABCC2 (MRP2)

  2007cited by this paper
• Comparative gene expression profiles of intestinal transporters in mice, rats and humans.

  2007cited by this paper
• ATP-binding cassette, subfamily G (ABCG family)

  2007cited by this paper
• Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks

  2007cited by this paper
• ABCG2 Expression Is an Independent Unfavorable Prognostic Factor in Esophageal Squamous Cell Carcinoma

  2007cited by this paper
• Chemoprevention of colorectal cancer – a new target needed?

  2007cited by this paper
• The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins.

  2007cited by this paper
• Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake.

  2007cited by this paper
• The inhibitors of apoptosis (IAPs) as cancer targets

  2007cited by this paper
• Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma

  2007cited by this paper
• Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides

  2007cited by this paper
• Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.

  2007cited by this paper
• Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.

  2006cited by this paper
• Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

  2006cited by this paper
• Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells.

  2006cited by this paper
• Overexpression ofBax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide

  2006cited by this paper
• Chemoresistance in solid tumours.

  2006cited by this paper
• DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

  2006cited by this paper
• c-FLIP inhibits chemotherapy-induced colorectal cancer cell death

  2006cited by this paper
• Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells

  2006cited by this paper
• Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.

  2006cited by this paper
• Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

  2006cited by this paper
• Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.

  2006cited by this paper
• Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency

  2006cited by this paper
• Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.

  2006cited by this paper
• Cellular functions of vaults and their involvement in multidrug resistance.

  2006cited by this paper
• Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux

  2006cited by this paper
• Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps.

  2006cited by this paper
• p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate

  2006cited by this paper
• Gastrointestinal stromal tumours: an update

  2006cited by this paper
• Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

  2006cited by this paper
• Role of copper transporters in the uptake and efflux of platinum containing drugs.

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.

  2006cited by this paper
• Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.

  2006cited by this paper
• Matrix Metalloproteinases Expression Correlates with Survival in Patients with Esophageal Squamous Cell Carcinoma

  2005cited by this paper
• Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

  2005cited by this paper
• Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells

  2005cited by this paper
• Hepatobiliary transporter expression in human hepatocellular carcinoma

  2005cited by this paper
• Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.

  2005cited by this paper
• MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).

  2005cited by this paper
• Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.

  2005cited by this paper
• Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins

  2005cited by this paper
• Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib

  2005cited by this paper
• Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2).

  2005cited by this paper
• Metabolism and Transport of Oxazaphosphorines and the Clinical Implications

  2005cited by this paper
• Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver

  2005cited by this paper
• Proapoptotic Effect on Normal and Tumor Intestinal Cells of Cytostatic Drugs with Enterohepatic Organotropism

  2005cited by this paper
• Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis

  2005cited by this paper
• Molecular mechanisms of drug resistance

  2005cited by this paper
• ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS

  2005cited by this paper
• Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.

  2005cited by this paper
• Evaluation of Nuclear Factor-κB, Urokinase-Type Plasminogen Activator, and HBx and Their Clinicopathological Significance in Hepatocellular Carcinoma

  2004cited by this paper
• The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts

  2004cited by this paper
• Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil Cytotoxicity

  2004cited by this paper
• Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells

  2004cited by this paper
• Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.

  2004cited by this paper
• Transporter-mediated drug delivery: recent progress and experimental approaches.

  2004cited by this paper
• Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

  2004cited by this paper
• Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase*

  2004cited by this paper
• Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line

  2004cited by this paper
• Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06.

  2004cited by this paper
• The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.

  2004cited by this paper
• The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.

  2004cited by this paper
• Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma.

  2004cited by this paper
• Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

  2004cited by this paper
• Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

  2004cited by this paper
• Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells

  2004cited by this paper
• Expression of IAPs and Alternative Splice Variants in Hepatocellular Carcinoma Tissues and Cells

  2004cited by this paper
• ABCG2 Pharmacogenetics

  2004cited by this paper
• Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model

  2004cited by this paper
• The equilibrative nucleoside transporter family, SLC29

  2004cited by this paper
• Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy

  2004cited by this paper
• Intracellular copper transport in mammals.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability.

  2004cited by this paper
• Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan

  2004cited by this paper
• Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips.

  2004cited by this paper

• Research progress in enhancing the precision of TCR-T cell therapy targeting cancer-testis antigens for cancer treatment in elderly patients

  2026cites this paper
• Combined nanodiamond-mediated drug delivery and upconversion phototherapy for enhanced liver cancer treatment.

  2025cites this paper
• Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity

  2024cites this paper
• In vitro activities and mechanisms of action of anti-cancer molecules from African medicinal plants: a systematic review.

  2024cites this paper
• The critical role of circular RNAs in drug resistance in gastrointestinal cancers

  2023cites this paper
• Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin

  2022cites this paper
• Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era

  2021cites this paper
• Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma

  2020cites this paper
• Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles

  2020cites this paper
• Molecular and cellular paradigms of multidrug resistance in cancer

  2020cites this paper
• Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment

  2020influential citation
• Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance

  2020cites this paper
• Effect of miR-21 on apoptosis in hepatoblastoma cell through activating ASPP2/p38 signaling pathway in vitro and in vivo

  2019cites this paper
• Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.

  2019cites this paper
• Gliotoxin Enhances Autophagic Cell Death via the DAPK1-TAp63 Signaling Pathway in Paclitaxel-Resistant Ovarian Cancer Cells

  2019cites this paper
• Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

  2019cites this paper
• Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.

  2019cites this paper
• Molecular Bases of Chemoresistance in Cholangiocarcinoma.

  2017cites this paper
• Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer

  2017cites this paper
• The role of p53 in cancer drug resistance and targeted chemotherapy

  2016influential citation
• Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

  2016cites this paper
• Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro

  2016cites this paper
• The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion.

  2014cites this paper
• MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential.

  2014cites this paper
• Toll‐like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis

  2014cites this paper
• Effect of matrine on transforming growth factor β1 and hepatocyte growth factor in rat liver fibrosis model.

  2014cites this paper
• Papel del receptor nuclear de ácidos biliares NR1H4 (“farnesoid X receptor”, FXR) en el control de la expresión de genes implicados en el desarrollo de quimiorresistencia. Características funcionales de sus isoformas

  2013cites this paper
• Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.

  2013cites this paper
• Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: role of the Akt/mTOR survival pathway and Bcl-2 family proteins.

  2013cites this paper
• Genetic Variants Involved in Intracellular Mechanisms of Chemoresistance to Anticancer Drugs Due to Changes in the Effect on Their Molecular Targets

  2013cites this paper
• BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.

  2013cites this paper
• Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

  2012influential citation
• Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.

  2012cites this paper
• No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.

  2012cites this paper
• Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells

  2012cites this paper
• Plasma Membrane Transporters in Modern Liver Pharmacology

  2012cites this paper
• Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy.

  2012cites this paper
• Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells.

  2012cites this paper
• Mechanism of Cell Adaptation: When and How Do Cancer Cells Develop Chemoresistance?

  2011influential citation
• CD 95 and TNFα-induced Apoptosis in Liver Metastases of Colorectal Carcinoma

  2010cites this paper
• Inhibition of Bcl‐2 and Bcl‐X enhances chemotherapy sensitivity in hepatoblastoma cells

  2010cites this paper
• CD95 and TNFα-induced apoptosis in liver metastases of colorectal carcinoma.

  2010cites this paper